To investigate the enzymatic functions of CD38 and the impact of CD38-targeting monoclonal antibodies on adenosinergic metabolism in multiple myeloma, highlighting the significance of these functions in therapeutic resistance.
Key Findings:
DARA and ISA promoted NAD+ degradation and increased ADPR levels in vitro, indicating enhanced metabolic activity.
In vivo, ADO levels in bone marrow plasma remained high during DARA treatment, while INO levels increased progressively, suggesting a shift in metabolic dynamics.
Persistent ADO production may contribute to a tolerogenic bone marrow niche, promoting immune evasion and therapeutic resistance.
Interpretation:
The sustained production of ADO during CD38-targeted therapy indicates ongoing immunosuppression, suggesting that combining CD38-directed antibodies with agents targeting adenosinergic signaling could enhance antitumor immunity and improve treatment outcomes.
Limitations:
The study primarily focuses on the enzymatic functions of CD38 without extensive exploration of other potential mechanisms of resistance, indicating a need for further research.
In vivo findings are based on a limited patient cohort receiving DARA monotherapy, which may not fully represent the broader patient population.
Conclusion:
Targeting CD38 enzymatic function and adenosinergic metabolism may improve therapeutic outcomes in multiple myeloma by overcoming immune suppression, warranting further investigation into combination therapies.
